Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.
RR/MDR-TB
Repeat
Xpert
detection
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
25
01
2021
accepted:
31
03
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
The Global Laboratory Initiative (GLI) guidelines recommend repeat for GeneXpertMTB/RIF (XpertMTB/RIF) in patients with a low pretest probability of rifampicin resistance (RR). This was a cross-sectional study using results of sputum specimens collected from participants screened for the STREAM 2 trial. We recruited all patients with XpertMTB/RIF RR-TB detected who were referred for RR/multidrug-resistant (MDR) TB treatment initiation at Mulago National Referral Hospital, Kampala, between September 2017 and October 2019. At baseline, smear microscopy, repeat XpertMTB/RIF, Xpert Ultra, and MTBDR A total of 126/130 patients had repeat XpertMTB/RIF results, of whom 97 (77.0%) had Our findings show a high false-positive rifampicin resistance rate in low-TB burden patients, which calls for repeat testing in order to prevent unnecessary prescription of anti-MDR-TB therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The Global Laboratory Initiative (GLI) guidelines recommend repeat for GeneXpertMTB/RIF (XpertMTB/RIF) in patients with a low pretest probability of rifampicin resistance (RR).
METHODS
METHODS
This was a cross-sectional study using results of sputum specimens collected from participants screened for the STREAM 2 trial. We recruited all patients with XpertMTB/RIF RR-TB detected who were referred for RR/multidrug-resistant (MDR) TB treatment initiation at Mulago National Referral Hospital, Kampala, between September 2017 and October 2019. At baseline, smear microscopy, repeat XpertMTB/RIF, Xpert Ultra, and MTBDR
RESULTS
RESULTS
A total of 126/130 patients had repeat XpertMTB/RIF results, of whom 97 (77.0%) had
CONCLUSIONS
CONCLUSIONS
Our findings show a high false-positive rifampicin resistance rate in low-TB burden patients, which calls for repeat testing in order to prevent unnecessary prescription of anti-MDR-TB therapy.
Identifiants
pubmed: 34189166
doi: 10.1093/ofid/ofab173
pii: ofab173
pmc: PMC8223903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab173Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : FIC NIH HHS
ID : D43 TW010132
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Diagn Microbiol Infect Dis. 2016 May;85(1):53-5
pubmed: 26915638
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33568463
Int J Tuberc Lung Dis. 2019 Mar 1;23(3):358-362
pubmed: 30940300
J Clin Microbiol. 2013 Aug;51(8):2641-5
pubmed: 23761146
J Clin Microbiol. 2013 Aug;51(8):2633-40
pubmed: 23761144
Int J Tuberc Lung Dis. 2016 Sep;20(9):1212-8
pubmed: 27510248
mBio. 2017 Aug 29;8(4):
pubmed: 28851844
Int J Tuberc Lung Dis. 2020 Mar 1;24(3):329-339
pubmed: 32228764
Acta Clin Belg. 2017 Jun;72(3):195-197
pubmed: 26400761
Int J Tuberc Lung Dis. 2012 Feb;16(2):206-8
pubmed: 22236921
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
J Antimicrob Chemother. 2020 May 1;75(5):1123-1129
pubmed: 32016320
Int J Tuberc Lung Dis. 2018 Sep 1;22(9):1056-1062
pubmed: 30092872
Open Forum Infect Dis. 2021 Jan 21;8(2):ofab034
pubmed: 33614819
Int J Tuberc Lung Dis. 2017 Jul 1;21(7):721-726
pubmed: 28633695
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29925643
Open Forum Infect Dis. 2020 Jul 05;7(8):ofaa279
pubmed: 32766385